Neonatal abstinence syndrome: Presentation and treatment considerations

Journal of Addiction Medicine

Volumn 10, Issue 4, 2016, Pages 217-223

  Kaltenbach, Karol ^a   Jones, Hendree E ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

neonatal abstinence syndrome; public policy; treatment

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; PHENOBARBITAL;

BREAST FEEDING; CLINICAL FEATURE; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; HEALTH IMPACT ASSESSMENT; HISTORY; HUMAN; NEWBORN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; TREATMENT RESPONSE; WITHDRAWAL SYNDROME; NEONATAL ABSTINENCE SYNDROME; PATHOPHYSIOLOGY;

HUMANS; NEONATAL ABSTINENCE SYNDROME;

EID: 84982853977     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000207     Document Type: Review

References (68)

1. Abdel-Latif ME, Piner J, Clews S, et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug dependent mothers. Pediatrics 2006; 117(6): e1163-e1169
2. Abrahams RR, Mackay-Dunn MH, Nevmerjitskaia V, et al. An evaluation of rooming-in among substance-exposed newborns in British Columbia. J Obstet Gynaecol Can 2010; 32: 866-871
3. Academy of Breastfeeding Medicine. ABM Clinical Protocol #21. Guidelines for breastfeeding and the drug dependent woman. Breastfeed Med 2009; 4(4): 225-228
4. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee No 524. Opioid abuse, dependence and addiction in pregnancy. Obstet Gynecol 2012; 119: 1070-1076
5. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009; 123(5): e849-e856
6. American Society of Anesthesiology. Practice guidelines for chronic pain management. Anesthesiology 1997; 6: 995-1004
7. Asti L, Magers JS, Keels E. A quality improvement project to reduce length of stay for neonatal abstinence syndrome. Pediatrics 2015; 135: e495
8. Backes CH, Backes CR, Gardner D, et al. Transitioning methadone treated infants from an inpatient to an outpatient setting. J Perinatol 2012; 36(6): 425-430
9. Blinick G, Wallach RC, Jerez E. Pregnancy in narcotic addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969; 105: 997-1003
10. Blinick G, Wallach RC, Jerez E, et al. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol 1976; 125: 135-142
11. CDC Fact Sheet on Fetal alcohol Spectrum Disorders. Available at: www.cdc.gov/ncbdd/fasd/documents. Accessed October 14, 2015
12. Creanga AA, Sabel JC, Ko JY, et al. Maternal drug use and its effect on neonates: a population-based study in Washington state. Obstet Gynecol 2012; 119(5): 924-933
13. D'Apolito K, Finnegan L. Assessing Signs and Symptoms of Neonatal Abstinence using the Finnegan Scoring Tool: An Inter-Observer reliability Program. Neo Advances LLC 2010. Available at: neoadvances.com. Accessed October 12, 2015
14. Desai RJ, Huybrechts KF, Hernandez-Diaz S, et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: a population based cohort study. BMJ 2015; 350: h2102
15. Desmond MM, Schwanecke RP, Wilson GS, et al. Maternal barbiturate utilization and neonatal withdrawal symptomatology. J Pediatr 1972; 80(2): 190-197
16. Dryden C, Young D, Hepburn M, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynecol 2009; 116(5): 665-671
17. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson NM, et al. eds. Primary Pediatric Care. 2nd ed. St. Louis, MO: Mosby 1992 1367-1378
18. Finnegan LP, Connaughton JF, Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2: 141-158
19. Franck LS, Harris SK, Soetenga DJ, et al. TheWithdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med 2008; 9: 573-580
20. Fulroth R, Phillips B, Durand DJ. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am J Diseases Child 1989; 113(6): 714-715
21. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed infants. Addiction 2012; 107(Suppl 1): 53-62
22. Gaalema DE, Heil SH, Badger GJ, et al. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend 2013; 133(1): 266-269
23. Gordon AL, Lopatko OV, Haslam RR, et al. Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine and methadone exposed infants. J Dev Orig Health Dis 2012; 3(4): 262-270
24. Gray L, Miller LW, Philipp BL. Breastfeeding is analgesic in healthy newborns. Pediatrics 2002; 109: 590-593
25. Green M, Suffet F. The Neonatal NarcoticWithdrawal Index: a device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981; 8: 203-213
26. Hall ES, Wexelblatt SL, Crowley M, et al. A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics 2014; 134(2): e527-e534
27. Hall ES, Wexelblatt SL, Crowley M. Implementation of a neonatal abstinence syndrome scoring weaning protocol. Pediatrics 2015; 136(4): e803-e810
28. Hand, DJ, Short VL, Abatemarco DJ, et al. Illicit drug use across pregnancy among benzodiazepine-using and non-using methadone maintained women. Presented at the Vermont Center on Behavior and Health. 3rd Annual Conference on Behavior Change, Health, and Health Disparities, Oct. 1, 2015, Burlington, VT
29. Hudak ML, Tan RC. Neonatal drug withdrawal. Pediatrics 2012; 129: e540-e560
30. Jansson LM, Dipietro JA, Elko A, et al. Infant autonomic functioning and neonatal abstinence. Drug Alcohol Depend 2010; 109: 198-204
31. Jones HE, Fielder A. Neonatal abstinence syndrome: historical perspective, current focus, future directions. Prevent Med 2015; 80: 12-17
32. Jones HE, Velez ML, McCaul ME, et al. Special treatment issues for women. In: Strain EC, Stizer M, editors. Methadone Treatment for Opioid Dependence. Baltimore, MD: Johns Hopkins University Press 1999. p. 251-280
33. Jones HE, Harrow C, O'Grady KE, et al. Neonatal abstinence scores in opioidexposed neonates: a blinded comparison. J Opioid Manag 2010; 6: 409-413
34. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331
35. Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend 2013; 131(3): 271-277
36. Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 2012; 107(suppl 1): 45-52
37. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn?. Neuropsychiatr Dis Treat 2013; 9: 1257-1266
38. Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134: e547-e561
39. Kraft WK, van Den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am 2012; 59: 1147-1165
40. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008; 122(3): e601-e607
41. Kraft WK, Dysart K, Greenspan JS, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid syndrome. Addiction 2011; 106(3): 574-580
42. Lind JN, Peterson EE, Lederer PA, et al. Infant and maternal characteristics in neonatal abstinence syndrome: selected hospitals in Florida, 2010-2011. MMWR Surveill Sumn 2015; 64(08): 213-216
43. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. Pragmatic evaluation of its efficacy. Clin Pediatr (Phila) 1975; 14(6): 592-594
44. Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Subst Use Misuse 1996; 31(2): 241-253
45. Meyer MC, Johnston AM, Crocker AM, et al. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med 2015; 9(2): 81-86
46. National Institute of Drug Abuse. Drug Dependence in Pregnancy: Clinical Management of Mother and Child. DHEW Publication No (ADM) 79-678, 1979
47. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States 2000-2009. JAMA 2012; 307: 1934-1940
48. Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr 1977; 90(4): 630-633
49. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012; 41(20): 180-190
50. Rementeria JL, Bhatt K.Withdrawal symptoms in neonates from intrauterine exposure to diazepam J Pediatr 1977 90 1 123-126
51. Sachs HC, American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and therapeutics into human breast milk. Pediatrics 2013; 132: e796-e809
52. SAMHSA. Medication assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 08-4214. Rockville, MD: Substance Abuse Mental Health Service Administration; 2005
53. SAMHSA Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No (SMA) 13-4795. Rockville, MD: Substance Abuse Mental Health Services Administration; 2013
54. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national study. J Perinatol 2006; 26(1): 15-17
55. Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone exposed neonates. Am J Obstet Gynecol 2008; 199. 396.e1-396.e7
56. Surran B, Visintainer P, Chamberlain S, et al. Efficacy of clonidine versus phenorbarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome; a prospective randomized clinical trial. J Perinatol 2013; 33: 954-959
57. Terplan M, Kennedy-Hendricks A, Chisolm M. Prenatal substance use: exploring assumptions of maternal unfitness. Subst Abuse 2015; 9(s2): 1-4
58. Velez M, Jansson LM. The opioid dependent mother and newborn dyad: nonpharmacologic care. J Addict Med 2008; 2(3): 113-120
59. Vermont Oxford Network. 2013. iNICQ 2013: Controversies in the Care of Infants and Families Affected by Neonatal Abstinence Syndrome. Available at: www.public.vtoxford.org. Accessed October 12, 2015
60. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence. J Addict Med 2011; 5(4): 293-299
61. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309910: 1821-1827
62. Warren MD, Miller AM, Taylor J, et al. Implementation of a statewide surveillance system for neonatal abstinence syndrome-Tennessee 2013. MMWR Surveill Sumn 2015; 64(05): 125-128
63. Welle-Strand GK, Skurtveit S, Jansson LM, et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 2013; 102(11): 1060-1066
64. Wiles JR, Iseman BI, Ward LD, et al. Current management of neonatal abstinence syndrome secondary to in-utero opioid exposure. J Pediatr 2014; 165(3): 440-446
65. Wiles JR, Iseman B, Mizuno T, et al. Pharmacokinetics of oral methadone in the treatment of neonatal abstinence syndrome: a pilot study. J Pediatr 2015; 167(6): 1214-1220
66. World Health Organization. Guidelines for the Identification and Management if Substance Use and Abuse Disorders in Pregnancy. Geneva, Switzerland: World Health Organization
67. Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr 1998; 19: 89-93
68. Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatr 1971; 48: 178-189